Records containing: Schizophrenia
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-04-16Examining the Efficacy of a Virtual Reality Cognitive Remediation Program for People Living With Psychosis
-
CLINICAL_TRIALS study record update · 2026-04-15A Phase 3, Multicenter, Double-Blind, Placebo-Controlled, Randomized Withdrawal Study to Assess the Efficacy of NBI-1117568 in Preventing Relapse of the Symptoms of Schizophrenia and to Assess the Safety and Tolerability of NBI-1117568 in Adults With Schizophrenia
-
CLINICAL_TRIALS study record update · 2026-04-15A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117570 in Adults With Schizophrenia Who Warrant Inpatient Hospitalization
-
CLINICAL_TRIALS study record update · 2026-04-15Enhancing Veteran-Clinical Collaboration in VA Psychosocial Rehabilitation and Recovery Centers
-
CLINICAL_TRIALS study record update · 2026-04-15A Global, Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1117568 in Adults With Schizophrenia Who Warrant Inpatient Hospitalization
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2026-04-15A Global, Phase 3, Multicenter, Open-Label Study to Assess the Long-Term Safety and Tolerability of NBI-1117568 in Adults With Schizophrenia
-
CLINICAL_TRIALS study record update · 2026-04-14The Effect of Adjuvant Curcumin Extract on Quality of Life and Interleukin-1 Beta (IL-1β) Levels in Patients With Schizophrenia Receiving Risperidone: A Randomized Clinical Trial
-
CLINICAL_TRIALS study record update · 2026-04-14Risk of Breakthrough Symptoms On Antipsychotic Maintenance Medication When Remitted Patients Are Treated With Long-Acting Injectable Medications
-
CLINICAL_TRIALS study record update · 2026-04-13A Randomized, Double-blind, Placebo-controlled Study to Determine Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
-
CLINICAL_TRIALS study record update · 2026-04-13Effectiveness and Adverse-effect Switch Evaluation
-
CLINICAL_TRIALS study record update · 2026-04-13Accelerated Neuromodulation of Prefrontal Circuitry During Clozapine Treatment
-
CLINICAL_TRIALS study record update · 2026-04-13A Randomized, Double-blinded, Placebo-controlled, Multicenter Study to Evaluate the Antipsychotic Efficacy and Safety of LB 102 in the Treatment of Adult Patients With Acute Schizophrenia
-
CLINICAL_TRIALS study record update · 2026-04-13Real-world Evaluation of Treatment Satisfaction and KarXT Utilization Registry (RESKU)
-
CLINICAL_TRIALS study record update · 2026-04-09Paired Associative Stimulation in the Dorsolateral Prefrontal Cortex in Patients With Schizophrenia: a Combined Transcranial Magnetic Stimulation and Electroencephalography Study Across the Life Span
-
CLINICAL_TRIALS study record update · 2026-04-09A 52 Week, Open Label Safety and Tolerability Study of LB-102 in Adult Patients With Schizophrenia
-
CLINICAL_TRIALS study record update · 2026-04-08An Open Label, Single Arm, Extension Trial to Examine Long-term Safety of Iclepertin Once Daily in Patients With Schizophrenia Who Have Completed Previous Iclepertin Phase III Trials (CONNEX-X)
-
CLINICAL_TRIALS study record update · 2026-04-08Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography
-
CLINICAL_TRIALS study record update · 2026-04-07A Double-Blind Placebo-Controlled Trial of the Synbiotic Compound Probio-Tec ABCG for Schizophrenia Patients With and Without Elevated Markers of Gastrointestinal Inflammation
-
CLINICAL_TRIALS study record update · 2026-04-07A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (13 to 17 Years of Age)
-
CLINICAL_TRIALS study record update · 2026-04-07Long-acting Injectable Antipsychotics for Mental Ill-Health in Pregnancy and Postpartum: An Observational Cohort Study
-
CLINICAL_TRIALS study record update · 2026-04-07A Randomized Controlled Trial of Acetazolamide for Patients With Treatment Resistant Schizophrenia
-
CLINICAL_TRIALS study record update · 2026-04-06Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar Disorder
-
CLINICAL_TRIALS study record update · 2026-04-02Evaluation of Effect of Low and High-frequencies of Repetitive Transcranial Magnetic Stimulation (rTMS) by the Suppression of P50 Evoked Potential Component (rTMS-P50)
-
CLINICAL_TRIALS study record update · 2026-04-01A 12-month Open-label, Phase 4 Multicenter Safety Study to Evaluate the Effect of KarXT on Voiding Dynamics and Urological Safety
-
CLINICAL_TRIALS study record update · 2026-04-01Ocrelizumab for Psychoses Possibly Caused by Synaptic Autoimmunity